Involvement of CD226+ NK Cells in Immunopathogenesis of Systemic Lupus Erythematosus

Zhan Huang, Binqing Fu, Song Guo Zheng, Xiaomei Li, Rui Sun, Zhigang Tian and Haiming Wei

*J Immunol* 2011; 186:3421-3431; Prepublished online 4 February 2011;
doi: 10.4049/jimmunol.1000569
http://www.jimmunol.org/content/186/6/3421

Supplementary Material

http://www.jimmunol.org/content/suppl/2011/02/04/jimmunol.1000569.DC1

References

This article cites 53 articles, 19 of which you can access for free at:
http://www.jimmunol.org/content/186/6/3421.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Dysfunction of immune systems, including innate and adaptive immunity, is responsible for the immunopathogenesis of systemic lupus erythematosus (SLE). NK cells are a major part of the innate immune system, and diminished populations of NK cells have been reported in SLE patients. However, the mechanisms behind this decrease and the role of NK cells in SLE pathogenesis remain poorly understood. In this study, we found that a deficiency of NK cells, especially CD226+ NK cells, is prominent in patients with active SLE. Meanwhile, expression of the CD226 ligands CD112 and CD155 on plasmacytoid dendritic cells is observed in SLE patients; thus, activation of CD226+ NK cells may be induced by CD226–ligand interactions. Furthermore, IFN-α, which is mainly produced by plasmacytoid dendritic cells, can mediate the activation-induced cell death of NK cells. Therefore, these processes likely contribute to the loss of NK cells in patients with active SLE. Despite the impaired cytotoxicity of peripheral NK cells in human SLE patients and mouse SLE models, we provide evidence that CD226+ NK cells infiltrate the kidneys of predisease MRL-lpr/lpr mice. Kidney-infiltrating NK cells displayed an activated phenotype and a marked ability to produce cytotoxic granules. These results suggest that, before apoptosis, activated NK cells can infiltrate tissues and, to some extent, mediate tissue injury by producing cytotoxic granules and immunoregulatory cytokines.

The Journal of Immunology, 2011, 186: 3421–3431.
of IFN-α may lead to the generation of autoimmune T and B cells (26). However, it is still unknown whether NK cell statuses, such as receptor expression and effector functions, are affected by IFN-α in SLE.

In this study, we found that NK cell populations were significantly reduced in SLE patients with active disease, and the majority of NK cells lost were CD226+ NK cells. Additionally, the elevated levels of serum IFN-α in SLE patients could mediate the activation-induced cell death (AICD) of NK cells, contributing to the loss of NK cells in SLE patients with active disease. Moreover, we found evidence that CD226+ NK cells infiltrated the kidneys of predisease MRL/lpr mice. Kidney-infiltrating NK cells acquired an activated phenotype and produced cytotoxic granules and immunoregulatory cytokines, which may induce tissue damage.

Materials and Methods

Patients

Ninety-nine consecutive patients (91 women and 8 men) with SLE from the Department of Rheumatology and Immunology, Anhui Provincial Hospital, were included in the study. All patients fulfilled at least four of the American College of Rheumatology 1997 revised criteria for SLE (32, 33). Disease activity was assessed by the SLE disease activity index (SLEDAI) (34). Among the 99 patients, 75 were diagnosed with active lupus (median age, 32.5 y; range: 13–66 y). Detailed characteristics of the patients with active disease are shown in Supplemental Table I. The mean SLEDAI of these patients was 12.89 (range, 4–30) at the time of blood sampling. The other 24 patients (median age, 33 y; range: 16–51 y), in long-term remission, were enrolled during the follow-up period. Remission was defined by resolution of clinical signs, normalization of laboratory findings, and minimal maintenance treatment. Treatments for the patients with active SLE were dependent on their diagnosis. Briefly, patients were treated with steroids (prednisolone, 1 mg/kg/d) and hydroxychloroquine (200–400 mg/d), alone or in combination. In addition to steroids and immunosuppressants, patients who were diagnosed with lupus nephritis received cyclophosphamide (600–800 mg once a month) or mycophenolate mofetil (300 mg twice daily) as complementary therapy. Steroids had been discontinued for >1 y in the patients in remission, with the exception of six who had received low-dose prednisone (10–15 mg/d) alone or in combination with antimalarials (hydroxychloroquine, 200 mg/d); no patient received any cytotoxic drugs. Peripheral blood samples, obtained from healthy donors at Hebei blood bank, served as controls. All blood samples were taken after informed consent by the donor and were collected following approval by the Institutional Review Board of the University of Science and Technology of China.

Mice

Female MRL/mp and MRL/lpr mice were purchased from Shanghai Experimental Animal Center, Chinese Science Academy (Shanghai, China). All mice were housed in a specific pathogen-free microenvironment and received care in compliance with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals. MRL/mp mice were between 8 and 15 wk of age. MRL/lpr mice were used at 9–33 wk of age.

Cell isolation

Human PBMCs from SLE patients and healthy donors were isolated by Ficoll-Hypaque (Solarbio, Beijing) density-gradient centrifugation. After washing twice, the PBMCs were resuspended in complete RPMI medium consisting of 10% FBS (both from Life Technologies), 100 U/ml penicillin, and 100 μg/ml streptomycin. To isolate mononuclear cells (MNCs), mice were sacrificed, and both kidneys were collected and decapsulated. Tissues were disrupted mechanically and then digested with collagenase D (Sigma) to make single-cell suspensions. After washing, pellets were resuspended in 40% Percoll (GE Healthcare), gently overlaid onto 30% Percoll, and centrifuged at 1261×g for 30 min at room temperature. Kidney MNCs were isolated from the Percoll interface and washed twice in PBS at 300 × g for 10 min at 4°C. Kidney MNCs were counted using a hemocytometer, and the absolute numbers of NK cells, B cells, and T cells in kidneys were calculated by multiplying the total number of kidney MNCs by the percentage of positive cells determined by flow cytometry. Murine splenic single-cell suspensions were prepared by passing each spleen through a 200-gauge stainless steel mesh. Erythrocytes were lysed with RBC lysis buffer (BioLegend), and the remaining cells were washed twice with PBS. The absolute numbers of NK cells, B cells, and T cells in splens were calculated as above.

Cell staining and flow cytometry

Human PBMCs and mouse splenic and kidney lymphocytes were prepared and stained with mAbs. FeRs were blocked using normal mouse serum or rat serum. Abs to the following Ags were used for staining human PBMCs: CD3 (clone:SK7), Lin-1 (SK7/3G9/S22CI/L1/L2/MF/99/NCAM16.2); CD3 (clone: CD4, CD8, CD24, CD90, CD45RA, CD4-18); CD4 (clone: CD4); CD16 (CD36); CD19 (HB19); CD56 (B159); CD69 (FN50); CD58 (GH175); CD94 (HP-3D9); CD112 (R2.523); CD123 (7G3); CD155b (CD-L); CD226 (DX11); NKGD2 (ID11); HLA-DR (G46-6); and NKP46 (9E2/NKP46) (BD PharMingen); CD155 (300097); NKGD2A (13.1411), and NKGC2 (13.4591) (R&D Systems); and CD158a (EB6), Vβ11 (C21), and Vα24 (C15) (Immunotech). For CD155 staining, cells were stained first with anti-CD155 and allophycocyanin–anti-mouse IgG and then additional staining was performed. For apoptosis detection, PBMCs were harvested and stained with anti-CD56 and anti-CD3 Abs. After two washes in cold binding buffer (10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, 2.5 mM CaCl2), cells were incubated with Annexin V (BD PharMingen) and propidium iodide (1 μg/ml) for 15 min at room temperature in the dark. Finally, binding buffer was added to a final volume of 400 μl, and flow cytometric analysis was performed. Abs to the following molecules were used to stain murine splenic or kidney lymphocytes: CD3e (145-2C11), CD19 (ID3), CD49b (DX-5), CD69 (H1.23) (all from BD PharMingen), and CD226 (10E5) (Biolegend). For intracellular-cytokine assays, after surface Ag staining, cells were fixed, permeabilized, and stained with Alexa Fluor-647–anti-IFN-α (7N4-1) (BD PharMingen), PE–anti-granzyme B (16G6), or allophycocyanin–anti-perforin (eBioMak-D) (eBioscience). Appropriate isotype controls were used in all experiments to estimate background fluorescence. Stained cells were analyzed using a FACSCalibur flow cytometer (Becton Dickinson), and data were analyzed with WinMDI version 2.9 software.

Intracellular IFN-γ detection

Freshly isolated mouse kidney MNCs (2 × 10^6/ml) were cultured with RPMI 1640 supplemented with 10% FBS in the presence of PMA (30 ng/ml) and ionomycin (1 μg/ml). One hour later, monensin (10 μg/ml) was added to prevent secretion of the induced cytokines. In one set of experiments (all of the stimulators were purchased from Sigma). Cells were harvested after culturing for 4 h at 37°C and 5% CO2 and stained with anti-CD3e and anti-DX5 Abs for 30 min at 4°C in the dark. After fixation and permeabilization, cells were stained with anti-IFN-γ (XMG1.2) (BD PharMingen) for 1 h at room temperature in the dark, washed twice with permeabilization buffer, and analyzed by flow cytometry. Appropriate isotype Abs were used as controls for intracellular cytokine detection.

ELISA for cytokine detection

To determine the cytokine levels in SLE patients, plasma samples were collected from all patients and controls and kept at −70°C until use. IFN-α was assayed using a standard sandwich ELISA Kit (BPL, Biomedical Laboratories).

In vitro cell culture and stimulation

A total of 1 × 10^6 human PBMCs was cultured in 24-well plates at 37°C in a 5% CO2 incubator. Cells were incubated in medium alone or with IFN-α (1000 U/ml; BPL Biomedical Laboratories) and then with IL-2 (100 U/ml; Changchun Institute of Biological Products) or IFN-α (1000 U/ml) plus IL-2 (100 U/ml) for 0, 24, 48, or 72 h. In another culture model, for cell activation and CD226 expression detection, PBMCs were cultured in the presence of 20% healthy control plasma or remission patient plasma or the same amount of active patient plasma with or without IFN-α–neutralizing Ab (10 μg/ml; BPL Biomedical Laboratories) for 0, 24, 48, or 72 h. For apoptosis detection, NK cell populations were enriched from whole blood by MACS kits. Briefly, total NK cells were stained with FITC-conjugated CD226 mAb (BD PharMingen). Subsequently, the cells were magnetically labeled with anti-FITC MicroBeads (Miltenyi Biotec). Two isolated cell subsets (2 × 10^6 cells per well) were cultured with plasma samples as described above. Cultured cells were harvested at the indicated time points, and activation and apoptosis of NK cells were analyzed by flow cytometry.

Measuring IFN-inducible gene expression

To assess the expression of genes (PRKR, IFIT1, MX1, and IFI44) that were predominantly induced by type I IFNs (IFIGs) (35), 1 × 10^5 PBMCs from healthy donors were cultured in six-well plates with medium. To study the
effect of donor plasma on gene expression, healthy donor PBMCs were stimulated with one of the following additions: IFN-α (1,000 U/ml), 20% plasma from healthy control or SLE patient in remission, or 20% plasma from SLE patient with active disease with or without IFN-α–neutralizing Ab (10 μg/ml). After an incubation of 24 h, the cells were lysed, and total RNA was extracted from each lysate via the phenol/chloroform method using TRizol reagent (Invitrogen, CA). Cellular RNA (2 μg) was used for cDNA synthesis. Semiquantitative real-time RT-PCR was performed using a SYBR Premix Ex Taq Perfect Real Time Kit (Takara) and a sequence detector (Rotor Gene 3000, Corbett Research). GAPDH was used as a housekeeping gene control. Primer sequences used were as follows: PRKR, 5′-CTT CCA TCT GAC TCA GGT TT-3′ (forward) and 5′-TGC TTC TGA CCG TAG TTA TT-3′ (reverse); IFIT1, 5′-CTC CTT GGG TCT CTC TAT AAA TTG-3′ (forward) and 5′-AGT CAG CAG CCA GTC TCA G-3′ (reverse); MX1, 5′-TAC CAG GAC TAC GAG ATT G-3′ (forward) and 5′-TGC CAG GAA GGT CTA TTA G-3′ (reverse); IFI44, 5′-CTC GGG TAG CAA TTA TTC CCT C-3′ (forward) and 5′-AGC CCA TAG CAT TCG TCT CAG-3′ (reverse); and GAPDH, 5′-GAA GAT GGT GAT GGG ATT TC-3′ (reverse).

H&E staining

For histological analysis, 10% formalin-fixed kidney tissue was embedded in paraffin and sectioned at 5 μm. After deparaffinization and dehydration, sections were stained with H&E. Sections were read on a fluorescent microscope (Axio Scope; Carl Zeiss) at ×100 and ×400. Microscopy images were acquired with a Carl Zeiss AxioCam HRc camera and AxioVision Software.

Statistical analysis

Data are expressed as mean ± SEM. One-way ANOVA was used to compare the significant differences among three or more groups, followed by the Bonferroni post hoc test. Analysis was completed using SPSS for Windows (version 10.1; SPSS). Statistical significance was defined as p < 0.05.

Results

Reduced proportion of circulating CD226+ NK cells in SLE patients with active disease

Because the immune state of SLE is poorly understood, involving abnormalities of the innate and adaptive arms of the immune system, we postulated that the frequency of circulating immune effector cells may be significantly altered in SLE patients. To test this hypothesis, the proportions of several lymphocyte subsets in the peripheral blood were determined by flow cytometry. Patients were divided into two groups based on disease activity, which was estimated by the SLEDAI. As shown in Fig. 1A–C, the absolute number and the proportion of CD3+CD56+ NK cells were significantly lower in SLE patients with active disease than in healthy controls and patients in remission. Similarly, the proportion and the absolute number of Vb11+Vα24+ NKT cells were also significantly lower in patients with active SLE than in healthy controls. We observed a higher proportion of CD3+CD19+ B cells.
in active SLE patients compared with healthy controls (Fig. 1A, 1B). However, the absolute number of B cells was lower in patients with active SLE than in controls (Fig. 1C), which is consistent with previous reports (36, 37). Additionally, representative examples (Fig. 1D) and cumulative data (Fig. 1E) demonstrated that the proportions of T cells (CD4+ or CD8+), myeloid DCs (MDCs; Lin1-CD11c-CD123+), and plasmacytoid DCs (PDCs; Lin1+HLA-DR+CD11c-CD123+) were not significantly altered between patients and controls. These data indicated that the proportion and absolute number of circulating NK cells are reduced in SLE patients with active disease, but they are gradually restored to near normal levels in remission.

The multiple functions of NK cells, such as natural cytotoxicity and cytokine secretion, can be regulated by interactions between inhibitory and activating families of NK receptors and their respective ligands (16). Because the frequency of NK cells was lower in patients with active SLE disease, we postulated that the expression of receptors on NK cells may be altered in these patients. To test this hypothesis, we compared the expression of a number of representative inhibitory and activating NK cell receptors, such as CD158b, NKG2A, CD94, CD85j, CD69, NKp46, NKG2C, NK2D, and CD16. With regard to inhibitory receptors, only CD158b showed expression levels significantly lower in active SLE and in remission. With respect to activating receptors, the proportion of NKG2C+ NK cells was lower in patients with active disease. Nonetheless, we did not observe any differences between the patient groups and the healthy controls in the expression of NKG2A, CD94, CD85j, CD69, NKp46, and NK2D by NK cells (data not shown). We next compared CD226 expression on circulating NK cells in SLE patients and healthy controls. Interestingly, the proportion of peripheral CD226+ NK cells was reduced from a peak of 88.36% in healthy controls to 16.19% in active disease (Fig. 2A). Nevertheless, the proportion of CD226+ NK cells returned to near normal levels in remission. Cumulative data for 20 healthy controls, 20 patients with active disease, and 15 remission patients are shown in Fig. 2B; the proportion of CD226+ NK cells was significantly lower in active disease than in healthy controls and patients in remission (p < 0.001 and p < 0.001, respectively). To determine whether a similar phenomenon could be observed in a mouse SLE model, we turned to the MRL/lpr mouse, which has proven valuable in analyses of SLE pathogenesis (38), to assess the proportion of CD226+ NK cells in peripheral circulation. Splenic lymphocytes were isolated from MRL/mp and MRL/lpr mice. As shown in Fig. 2C, the proportion of CD3+ DX5+ NK cells was reduced in MRL/lpr mice at 30 wk of age (diseased) compared with MRL/lpr mice at 9 wk of age (predisease) and control MRL/mp mice. Also, the proportion of CD226+ NK cells was lower in diseased MRL/lpr mice compared with predisease MRL/lpr mice and MRL/mp mice (p < 0.001 and p < 0.001, respectively; Fig. 2C, 2D). These data suggested that most of the NK cells lost in active SLE and diseased MRL/lpr mice might be CD226+, as noted in Fig. 2.

**Dynamic changes in CD226+ NK cell populations in SLE patients are associated with disease activity**

To further assess the status of CD226 expression on NK cells in SLE patients, dynamic observations were made on 15 SLE patients during therapy. These patients were diagnosed with SLE for the first time; they had clinically active disease, as determined by the presence of rash, fever, serositis, or glomerulonephritis. At the first time of blood drawing (day 0), none had received any drugs. During hospitalization, 13 patients were taking prednisolone (1 mg/kg/d) and 2 were taking hydroxychloroquine (200 mg twice daily) in addition to the steroids. None were treated with immunosuppressive drugs. Blood was drawn for study at the indicated time points during therapy. We were then able to make a dynamic analysis of NK cell proportions and CD226 expression by flow cytometry. As shown in Fig. 3A, the proportion of NK cells was

---

**FIGURE 2.** Downregulated expression of CD226 on NK cells from SLE patients and MRL/lpr mice with active disease. Freshly isolated PBMCs were stained with anti-CD3, CD56, and CD226 mAbs. A, NK cells were gated (top panel), and expression of CD226 was analyzed (bottom panel) on NK cells from healthy controls, patients with active SLE, and patients in remission. B, Cumulative data are shown for the mean (± SEM) proportion of CD226+ NK cells of healthy controls, patients with active SLE, and patients with SLE in remission. Significance was determined using one-way ANOVA, followed by the Bonferroni post hoc test. C, Freshly isolated mouse splenic lymphocytes were stained with anti-CD3, DX5, and CD226 mAbs. Representative flow cytometric dot plots show the proportion of NK cells (top panel) and the expression of CD226 on NK cells (bottom panel) in an MRL/mp mouse, a diseased MRL/lpr mouse, and a predisease MRL/lpr mouse. D, Cumulative data are shown for the mean (± SEM) proportion of CD226+ NK cells of MRL/mp mice, diseased MRL/lpr mice, and predisease MRL/lpr mice. Significance was determined using one-way ANOVA, followed by the Bonferroni post hoc test.
markedly lower in six patients (four received prednisolone, two were treated with prednisolone and hydroxychloroquine) during the exacerbation stage (left panel). Further analysis identified a sustained decrease in CD226* NK cells in these patients during therapy (right panel). Two representative examples of CD226 expression after gating on CD3*CD56* NK cells from the six patients are shown in Fig. 3B. By contrast, the conditions of the other nine patients were improved after medication, all of whom received prednisolone as monotherapy, and the NK cell populations were not significantly reduced. Moreover, the proportion of NK cells in patients 6 and 9 increased markedly during therapy (Fig. 3C, left panel). Interestingly, the proportion of CD226* NK cells was significantly increased in the nine patients during therapy (Fig. 3C, right panel). Two representative examples from the nine patients are shown in Fig. 3D. Taken together, these data suggested that the decreased expression of CD226 on NK cells correlated with disease activity in SLE patients, and therapy might restore the frequency of CD226* NK cells, at least in some patients.

Expression of the CD226 ligands CD112 and CD155 on DCs in SLE patients

Because CD226 is a surface molecule that transduces activating signals through interactions with its ligands, we next evaluated the expression of two CD226-specific ligands, CD112 and CD155, on circulating PBMCs in SLE patients. As shown in Fig. 4A and 4C, CD112 and CD155 expression on T cells, B cells, and MDCs was detectable (2–5%) in SLE patients and healthy donors. Interestingly, CD226 ligands were mostly expressed on PDCs in SLE patients and healthy controls. CD112 expression levels on PDCs were slightly increased in SLE patients compared with healthy controls, and there were no statistical differences in CD112 and CD155 expression on PDCs between the two groups (Fig. 4B, 4D). Considering that CD226 is highly expressed on NK cells, whereas CD226-specific ligands CD112 and CD155 are substantially expressed on PDCs in SLE patients. It is possible that the interaction between CD226 ligands and CD226 plays a significant role in the pathogenesis of SLE.

Activation and apoptosis of CD226* NK cells are induced by IFN-α from active SLE plasma

Given that the frequency of NK cells (Fig. 1), especially CD226* NK cells (Fig. 2), was markedly lower in patients with active SLE, we hypothesized that the status of CD226* NK cells could be influenced by the cytokine milieu in SLE patients. Therefore, several proinflammatory and immunoregulatory cytokines were measured by ELISA in plasma obtained from SLE patients and healthy controls (data not shown). As shown in Fig. 5A, the levels of IFN-α in plasma samples from patients with active SLE (n = 32) were higher than those in healthy controls (n = 17; p = 0.028) and patients in remission (n = 13; p = 0.048). Moreover, levels of IFN-α were high in three patients with active disease but declined to normal levels after therapy (Fig. 5B).

To further test the IFN-α activity in plasma from SLE patients, PBMCs from healthy donors were stimulated with different plasma samples, and the relative expression of four IFIGs (PRKR, IFIT1, MX1, and IFI44) in PBMCs was tested after 24 h of incubation. As shown in Fig. 5C, IFIGs were induced by plasma from patients with active disease, but IFIGs were not induced by plasma from healthy controls and patients in remission. Neutralizing Abs to IFN-α inhibited the activity of active SLE plasma. Because IFN-α is produced primarily by PDCs (39–42), we tested IFN-α production by PDCs in SLE patients and healthy controls. Freshly isolated PBMCs were detected without stimuli, and the amount of IFN-α produced by PDCs was analyzed by flow cytometry. As shown in Fig. 5D, IFN-α was detectable from PDCs in SLE patients but not in healthy controls. These data confirmed the elevated levels of IFN-α in SLE observed in earlier studies.

We then postulated that high levels of IFN-α may affect the functions and survival of NK cells in SLE patients. To assess this
activation marker CD69. Additionally, the CD226 + subset of NK from patients with active SLE. However, the CD226 was markedly upregulated after 24 h of stimulation with plasma was examined. Flow cytometry. Expression of the indicated ligands (blue graphs) relative to isotype-matched controls (gray graphs) on T cells, B cells, MDCs, and PDCs was investigated. These data indicated that the high expression of CD112 and CD226+ NK cells. These data indicated that the high expression of CD69 on total NK cells and gated CD226 + NK cells. Furthermore, purified CD226 + and CD226 - NK cells. These data indicated that the high expression of CD226 + NK cells. Therefore, the reduced frequency of apoptotic CD226 + NK cells.

Also, in the two cell-culture experiments, PBMCs isolated from healthy controls were stimulated with IL-2 (100 U/ml), IFN-α (1000 U/ml), or IFN-α plus IL-2. The activation status of NK cells gated from PBMCs was assessed. As seen in Fig. 6A, after 48 h of stimulation with IFN-α, NK cells upregulated the activation marker CD69. Additionally, the CD226 - subset of NK cells was activated. Furthermore, combined treatment with IFN-α and IL-2 induced higher levels of CD69 expression on total NK cells and CD226 + NK cells. By contrast, the expression of CD69 on CD226 - NK cells was not upregulated after stimulation. We next investigated whether the plasma factor(s) of SLE patients could induce NK cell activation. PBMCs isolated from healthy controls were stimulated with plasma from healthy controls, SLE patients in remission, or patients with active SLE (plasma levels of IFN-α from active patients were measured by ELISA, concentrations ranged from 13–180 pg/ml). As shown in Fig. 6B, the expression of CD69 on total NK cells and gated CD226 + NK cells was markedly upregulated after 24 h of stimulation with plasma from patients with active SLE. However, the CD226 - NK cells were not obviously activated. Meanwhile, to determine whether the activation of NK cells was primarily stimulated by IFN-α from the plasma of patients with active SLE, we added a neutralizing mAb against IFN-α to active SLE plasma. As shown in Fig. 6B, the neutralizing mAb substantially reduced the activation of NK cells and CD226 + NK cells. These data indicated that the high levels of IFN-α in SLE induced an activated phenotype in NK cells, particularly in CD226 + NK cells.

In SLE patients, several organs, including the skin, blood vessels, lungs, and kidneys, are damaged. Therefore, we postulated that CD226 + NK cells, when activated by IFN-α, play a role in tissue damage in SLE. We used the MRL/lpr mouse to test this possibility. Fig. 8A shows representative kidney sections stained with H&E from MRL/mp mice, predisease MRL/lpr mice, and diseased MRL/lpr mice. Cellular infiltration and glomerular lesions were seen in diseased 21-wk-old MRL/lpr mice. By contrast, no sign of inflammation or cellular proliferation was observed in MRL/mp or 9-wk-old MRL/lpr predisease mice. To better characterize the status of infiltrating lymphocytes in the kidneys, absolute numbers of T, B, and NK cells were calculated. The number (Fig. 8F) and proportion (data not shown) of T cells in MRL/lpr mice kidneys (Fig. 8F) and spleens (data not shown) were increased compared with MRL/mp mice. The number of B cells in predisease MRL/lpr mice kidneys was higher than in diseased MRL/lpr and MRL/mp mice (Fig. 8E), but the proportion of B cells was reduced in MRL/lpr mice kidneys compared with MRL/mp mice (data not shown).

Activated CD226 + NK cells mediate kidney injury in MRL/lpr mice

In SLE patients, several organs, including the skin, blood vessels, lungs, and kidneys, are damaged. Therefore, we postulated that CD226 + NK cells, when activated by IFN-α, play a role in tissue damage in SLE. We used the MRL/lpr mouse to test this possibility. Fig. 8A shows representative kidney sections stained with H&E from MRL/mp mice, predisease MRL/lpr mice, and diseased MRL/lpr mice. Cellular infiltration and glomerular lesions were seen in diseased 21-wk-old MRL/lpr mice. By contrast, no sign of inflammation or cellular proliferation was observed in MRL/mp or 9-wk-old MRL/lpr predisease mice. To better characterize the status of infiltrating lymphocytes in the kidneys, absolute numbers of T, B, and NK cells were calculated. The number (Fig. 8F) and proportion (data not shown) of T cells in MRL/lpr mice kidneys (Fig. 8F) and spleens (data not shown) were increased compared with MRL/mp mice. The number of B cells in predisease MRL/lpr mice kidneys was higher than in diseased MRL/lpr and MRL/mp mice (Fig. 8E), but the proportion of B cells was reduced in MRL/lpr mice kidneys compared with MRL/mp mice (data not shown). Although the proportion of NK cells in predisease MRL/lpr mice kidneys was similar to that of MRL/mp mice (data not shown), the
absolute number of NK cells was significantly higher in the kidneys of predisease MRL/lpr mice (2.76 ± 0.49 × 10^5) compared with diseased MRL/lpr mouse (0.71 ± 0.09 × 10^5) and MRL/mp mouse (0.31 ± 0.02 × 10^5) (p = 0.025 and p = 0.011, respectively; Fig. 8B). Furthermore, most of the kidney-infiltrating NK cells in predisease MRL/lpr mice were CD226 + NK cells (Fig. 8C), and CD69 expression on kidney NK cells was expanded from a baseline of ∼1.5% in MRL/mp mice to 10–15% in predisease MRL/lpr mice and 20–30% in diseased MRL/lpr mice (p = 0.009 and p = 0.032, respectively; Fig. 8D). Conversely, the number of NK cells was similar in the spleens of MRL/lpr and MRL/mp mice, whereas the proportion of NK cells was lower in the spleens of MRL/lpr mice (data not shown).

We showed that NK cells, especially CD226 + NK cells, infiltrated into predisease MRL/lpr mouse kidneys (Fig. 8B, 8C). In addition to their greater numbers, NK cells in predisease and diseased MRL/lpr kidneys exhibited an enhanced activated phenotype (Fig. 8D). In light of these results, we postulated that these NK cells would be involved in the pathogenesis of renal injury by producing immunoregulatory cytokines and cytotoxic granules. As shown in Fig. 9, NK cells from predisease MRL/lpr kidneys, as well as diseased MRL/lpr kidneys, produced increased amounts of IFN-γ, granzyme B, and perforin compared with NK cells from MRL/mp kidneys. Furthermore, the number of T cells was higher in MRL/lpr kidneys, and activation and production of IFN-γ and granzyme B were enhanced in T cells from MRL/lpr mice compared with MRL/mp mice (data not shown). Taken together, these data suggested that activated CD226 + NK cells are responsible, at least to some extent, for the kidney injury observed in SLE.

Discussion
It has long been known that the proportion and absolute number of NK cells are significantly reduced in SLE patients. However, the mechanism underlying this reduction remains unclear. Our data showed, for what we believe is the first time, that the reduced proportion and absolute number of circulating NK cells in SLE patients are due to AICD mainly mediated by IFN-α. Our results indicated that IFN-α levels were high in patients with active disease but were reduced to normal levels in remission. Other cytokines, including IFN-γ, IL-12, and IL-2, did not increase in SLE patients compared with healthy controls (data not shown). It was reported that high levels of IFN-α contribute to the...
However, to our knowledge, the role of IFN-α in regulating the frequency of NK cells in SLE has not been studied. In our study, NK cells isolated from healthy controls showed an activated phenotype and high rate of apoptosis after being stimulated by plasma from patients with active SLE. Additionally, this induction could be blocked by a neutralizing IFN-α mAb. Along with the observed reduction in NK cell numbers, the cytotoxicity of NK cells was impaired in SLE patients. Previously published data demonstrated that IFN from SLE patients cannot boost NK cell cytotoxicity ex vivo. Our results extend this finding, showing that although the cytotoxicity of peripheral NK cells was impaired in human SLE patients and mouse SLE models (data not shown), increased expression of CD69 on NK cells could be induced by patient plasma through an IFN-α-dependent mechanism. Furthermore, the kidney-infiltrating NK cells of MRL/lpr mice exhibited an enhanced ability to produce cytotoxic granules and IFN-γ. In addition, abnormal expression of DAP12 molecules may account for the impaired function of NK cells in patients with SLE (43). Interestingly, increased numbers of CD226+ NK cells are present in the kidney of predisease MRL/lpr mice; it is...
possible that the reduction in the circulating CD226+ NK cells results from these cells becoming activated, leaving the periphery, and infiltrating the kidney to play a role in the disease process. Indeed, we further found a sharp decline in CD226+ NK cells in diseased MRL/lpr mice, which may also be caused by activation-induced apoptosis. Taken together, these results suggested that activated CD226+ NK cells may undergo AICD after infiltrating the kidney and exerting their influence on disease development, which would eventually lead to the decrease in the number of NK cells.

Another interesting finding in this study was the observation that most of the NK cells lost in SLE are CD226+. CD226, an activating receptor and adhesion molecule, is involved in NK cell-mediated lysis of tumor cells from different origins. The expression of CD226 on NK cells is considered to be a key index in several human diseases, including HIV (21) and multiple myeloma (44), but it has not been evaluated in SLE. Our results indicated that the altered proportions of CD226+ NK cells are relevant to disease progression. In general, CD226+ NK cells decline in patients during the exacerbation stage. By contrast, they return to normal levels during remission. Interestingly, a similar phenomenon was observed in mouse SLE models. Moreover, our data suggested that the expression of other receptors, such as the inhibitory receptors NKG2A, CD94, and CD85j and the activating receptors CD69, NKp46, NKG2C, NKG2D, and CD16, on NK cells were not altered in SLE patients. Evidence from recent studies indicated that reduced expression of CD226 increased sensitivity to apoptosis in NKT cells from SLE patients (45). In our cell-culture experiments, plasma from patients with active disease induced enhanced CD226+ NK cell apoptosis via an IFN-α-dependent mechanism. It is likely that the markedly reduced proportion of CD226+ NK cells is related to this process. Thus, similar mechanisms may be involved in the apoptosis of NK cells in SLE patients. Given that dynamic alterations in CD226+ NK cells are relevant to disease activity, we suggest that the frequency of CD226+ NK cells may be used as a clinical index for SLE.

Type I IFNs (IFN-I) can be produced by many cell types in vitro when cells are exposed to different microorganisms. For example, monocyte/macrophages could produce IFN-I in response to influenza and Sendai viruses (46). Also, resident renal cells produced IFN-I in an experimental model of autoantibody-mediated glomerulonephritis (47). However, PDCs, the major source of IFN-α...

**FIGURE 8.** Enrichment of NK cell numbers in the kidneys of MRL/lpr mice. A, Representative kidney sections stained with H&E from an MRL/mp mouse, a 9-wk-old MRL/lpr mouse, and a 21-wk-old MRL/lpr mouse. At the time of sacrifice, the kidneys were removed and sectioned before staining with H&E (original magnification ×100 [top row] and ×400 [bottom row]). Kidney MNCs were obtained from MRL/mp and predisease and diseased MRL/lpr mice. Absolute numbers of NK cells (B), CD226+ NK cells (C), B cells (E), and T cells (F) were calculated as detailed in Materials and Methods. Results are expressed as the number of cells per two kidneys. D, NK cells from kidney MNCs in MRL/mp and predisease and diseased MRL/lpr mice were assayed ex vivo for CD69 expression. Results are expressed as the mean ± SEM for each group. Significance was determined using one-way ANOVA, followed by the Bonferroni post hoc test.
NK cells can migrate into the target organs of autoimmunity (53). In SLE patients, it was reported in the murine system that peripheral these activated NK cells exert their functions before apoptosis in any stimulation, production of IFN-α was detectable in PDCs from patients with active SLE but not from healthy controls. Furthermore, expression of the CD226 ligands CD112 and CD155 on DCs (MDCs and PDCs) was observed in SLE patients. Evidence from previous studies suggested that NK cells are able to modulate the function of DCs, either by promoting their maturation or by killing them (49, 50). For example, engagement of NKp30, an activating receptor on NK cells, results in the activation of cytotoxicity and the production of cytokines, such as IFN-γ and TNF-α (49), which promote DC maturation (50). In contrast, MDCs can activate NK cells via cell–cell contact (51). Furthermore CD226–ligand interactions might be primarily involved in the recognition and killing of DCs (52). We postulate that the CD226–ligand interaction induces the apoptosis of CD226+ NK cells and subsequently downregulates the ability of NK cells to kill PDCs in SLE patients. Thus, PDCs persist in SLE patients, yielding the function of DCs, either by promoting their maturation or by killing them (49, 50).

Given that IFN-I plays a pivotal role in the etiopathogenesis of SLE, IFN-α might be considered a valuable therapeutic target in SLE. A published phase I trial revealed that the overexpressed IFN-α/β-inducible genes in whole blood and skin lesions were inhibited in the subjects treated with anti–IFN-α mAb. According to our results, the activation of NK cells, as well as tissue injury induced by infiltrating NK cells, might be inhibited by using an IFN-α antagonist in SLE patients. This may play an important role in relieving disease activity and tissue inflammation.

In summary, our results showed that NK cell populations were significantly reduced in patients with active SLE but not in patients in remission or healthy controls. The major NK cell population affected consists of CD226+ NK cells in patients with active disease. It seems that dynamic alterations in CD226+ NK cell populations in patients are relevant to disease activity. Furthermore, we found that, in SLE patients, PDCs sustain the production of IFN-α, and the high levels of IFN-α in active SLE can mediate AICD of NK cells. Meanwhile, the reduction in CD226+ NK cell populations is mediated by increased apoptosis. Additionally, in a mouse model of SLE, CD226+ NK cells infiltrate the kidneys during disease progression and display an activated phenotype. Finally, activated NK cells may damage kidneys to some extent by producing cytotoxic granules and immunoregulatory cytokines.

Induced by nucleic acid-containing immune complexes, were shown to account for the etiopathogenesis of SLE. Once stimulated by self apoptosis-derived DNA- and/or RNA- or small nuclear ribonucleoprotein particle-containing immune complexes, PDCs migrate from the blood into inflamed sites, including the skin and kidney (39–42). PDCs do not usually produce measurable amounts of IFN-α unless stimulated by microorganisms or their constituents (48). However, our data demonstrated that, without any stimulation, production of IFN-α was detectable in PDCs from patients with active SLE but not from healthy controls. Furthermore, evidence from previous studies suggested that NK cells are able to modulate the function of DCs, either by promoting their maturation or by killing them (49, 50). For example, engagement of NKp30, an activating receptor on NK cells, results in the activation of cytotoxicity and the production of cytokines, such as IFN-γ and TNF-α (49), which promote DC maturation (50). In contrast, MDCs can activate NK cells via cell–cell contact (51). Furthermore CD226–ligand interactions might be primarily involved in the recognition and killing of DCs (52). We postulate that the CD226–ligand interaction induces the apoptosis of CD226+ NK cells and subsequently downregulates the ability of NK cells to kill PDCs in SLE patients. Thus, PDCs persist in SLE patients, yielding the characteristic sustained IFN-α production observed in SLE, and IFN-α further promotes the activation-induced apoptosis of NK cells. Therefore, we suggest that further investigations aimed at modulating CD226 expression on NK cells in SLE patients may be an attractive avenue of experimental therapeutics.

Once stimulated by IFN-α, NK cells maintain an activated phenotype until apoptosis. Additionally, the cytotoxicity of peripheral NK cells was proved to be impaired in SLE patients. So how do these activated NK cells exert their functions before apoptosis in SLE patients? It was reported in the murine system that peripheral NK cells can migrate into the target organs of autoimmunity (53). In this study, we chose a mouse model that mimics human SLE. Our results indicated that peripheral NK cells in MRL/lpr mice did not produce higher levels of IFN-γ and perforin compared with normal controls, similar to SLE patients. Nevertheless, NK cells were recruited from the periphery into kidneys in predisease MRL/lpr mice, and most of the infiltrating NK cells belonged to the CD226+ subset. Furthermore, kidney-infiltrating NK cells in MRL/lpr mice displayed an activated phenotype, including upregulated expression of CD69 and high production of cytotoxic granules and IFN-γ, which may contribute to inflammation and eventual kidney injury. Therefore, these activated NK cells may infiltrate and damage tissues during the disease process.

Given that IFN-I plays a pivotal role in the etiopathogenesis of SLE, IFN-α might be considered a valuable therapeutic target in SLE. A published phase I trial revealed that the overexpressed IFN-α/β-inducible genes in whole blood and skin lesions were inhibited in the subjects treated with anti–IFN-α mAb. According to our results, the activation of NK cells, as well as tissue injury induced by infiltrating NK cells, might be inhibited by using an IFN-α antagonist in SLE patients. This may play an important role in relieving disease activity and tissue inflammation.

In summary, our results showed that NK cell populations were significantly reduced in patients with active SLE but not in patients in remission or healthy controls. The major NK cell population affected consists of CD226+ NK cells in patients with active disease. It seems that dynamic alterations in CD226+ NK cell populations in patients are relevant to disease activity. Furthermore, we found that, in SLE patients, PDCs sustain the production of IFN-α, and the high levels of IFN-α in active SLE can mediate AICD of NK cells. Meanwhile, the reduction in CD226+ NK cell populations is mediated by increased apoptosis. Additionally, in a mouse model of SLE, CD226+ NK cells infiltrate the kidneys during disease progression and display an activated phenotype. Finally, activated NK cells may damage kidneys to some extent by producing cytotoxic granules and immunoregulatory cytokines.